Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenström macroglobulinemia cells

References

• Dimopoulos MA, Kyle RA, Anagnostopoulos A, et al. Diagnosis and management of Waldenstrom’s macroglobulinemia. J Clin Oncol 2005;23:1564–1577.
   PubMed Web of Science ®Google Scholar
• Treon SP, Hatjiharissi E, Merlini G. Waldenstrom’s macrogloblinemia/lymphoplasmacytic lymphoma. Cancer Treat Res 2008;142:211–242.
   PubMedGoogle Scholar
• Hatjiharissi E, Mitsiades CS, Ciccarelli BT, et al. Comprehensive molecular characterization of malignant and microenviromental cells in Waldenstrom’s macroglobulinemia by gene expression profiling. Blood 2007;110(Suppl. 1): Abstract 3174.
   Google Scholar
• Eot-Houllier G, Fulcrand G, Magnaghi-Jaulin L, et al. Histone deacetylase inhibitors and genomic instability. Cancer Lett 2009;274:169–176.
   PubMed Web of Science ®Google Scholar
• Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002;1:287–299.
   PubMed Web of Science ®Google Scholar
• Dai Y, Rahmani M, Dent P, et al. Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation. Mol Cell Biol 2005;25:5429–5444.
   PubMed Web of Science ®Google Scholar
• Finnin MS, Donigian JR, Cohen A, et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999;401:188–193.
   PubMed Web of Science ®Google Scholar
• Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000;92:1210–1216.
   PubMed Web of Science ®Google Scholar
• Richon VM, Sandhoff TW, Rifkind RA, et al. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 2000;97:10014–10019.
   PubMed Web of Science ®Google Scholar
• Ruefli AA, Ausserlechner MJ, Bernhard D, et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 2001;98:10833–10838.
   PubMed Web of Science ®Google Scholar
• Rosato RR, Grant S. Histone deacetylase inhibitors: insights into mechanisms of lethality. Expert Opin Ther Targets 2005;9:809–824.
   PubMed Web of Science ®Google Scholar
• Dokmanovic M, Marks PA. Prospects: histone deacetylase inhibitors. J Cell Biochem 2005;96:293–304.
   PubMed Web of Science ®Google Scholar
• Dubrez-Daloz L, Dupoux A, Cartier J. IAPs: more than just inhibitors of apoptosis proteins. Cell Cycle 2008;7:1036–1046.
   PubMed Web of Science ®Google Scholar
• Salvesen GS, Duckett CS. IAP proteins: blocking the road to death’s door. Nat Rev Mol Cell Biol 2002;3:401–410.
   PubMed Web of Science ®Google Scholar
• Perrelet D, Ferri A, Liston P, et al. IAPs are essential for GDNF-mediated neuroprotective effects in injured motor neurons in vivo. Nat Cell Biol 2002;4:175–179.
   PubMed Web of Science ®Google Scholar
• Potts MB, Vaughn AE, McDonough H, et al. Reduced Apaf-1 levels in cardiomyocytes engage strict regulation of apoptosis by endogenous XIAP. J Cell Biol 2005;171:925–930.
   PubMed Web of Science ®Google Scholar
• Conte D, Holcik M, Lefebvre CA, et al. Inhibitor of apoptosis protein cIAP2 is essential for lipopolysaccharide-induced macrophage survival. Mol Cell Biol 2006;26:699–708.
   PubMed Web of Science ®Google Scholar
• Warnakulasuriyarachchi D, Cerquozzi S, Cheung HH, et al. Translational induction of the inhibitor of apoptosis protein HIAP2 during endoplasmic reticulum stress attenuates cell death and is mediated via an inducible internal ribosome entry site element. J Biol Chem 2004;279:17148–17157.
   PubMed Web of Science ®Google Scholar
• Lewis SM, Holcik M. IRES in distress: translational regulation of the inhibitor of apoptosis proteins XIAP and HIAP2 during cell stress. Cell Death Differ 2005;12:547–553.
   PubMed Web of Science ®Google Scholar
• Warnakulasuriyarachchi D, Ungureanu NH, Holcik M. The translation of an antiapoptotic protein HIAP2 is regulated by an upstream open reading frame. Cell Death Differ 2003;10:899–904.
   PubMed Web of Science ®Google Scholar
• Hamanaka RB, Bobrovnikova-Marjon E, Ji X, et al. PERK-dependent regulation of IAP translation during ER stress. Oncogene 2009;28:910–920.
   PubMed Web of Science ®Google Scholar
• Zweifach A, Lewis SA. Characterization of a partially degraded Na+ channel from urinary tract epithelium. J Membr Biol 1988;101:49–56.
   PubMed Web of Science ®Google Scholar
• Hunter T. Oncoprotein networks. Cell 1997;88:333–346.
   PubMed Web of Science ®Google Scholar
• Milella M, Kornblau SM, Estrov Z, et al. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest 2001;108:851–859.
   PubMed Web of Science ®Google Scholar
• Lee ER, McCool KW, Murdoch FE, et al. Dynamic changes in histone H3 phosphoacetylation during early embryonic stem cell differentiation are directly mediated by mitogen- and stress-activated protein kinase 1 via activation of MAPK pathways. J Biol Chem 2006;281:21162–21172.
   Google Scholar
• Lane SW, Scadden DT, Gilliland DG. The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood 2009;114:1150–1157.
   PubMed Web of Science ®Google Scholar
• Chen CI, Kouroukis CT, White D, et al. Bortezomib is active in patients with untreated or relapsed Waldenstrom’s macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1570–1575.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Gertz MA, Kastritis E, et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom’s Macroglobulinemia. J Clin Oncol 2009;27:120–126.
   PubMed Web of Science ®Google Scholar
• Heider U, vonMetzler I, Kaiser M, et al. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. Eur J Haematol 2008;80:133–142.
   PubMed Web of Science ®Google Scholar
• Mitsiades CS, Hayden PJ, Anderson KC, et al. From the bench to the bedside: emerging new treatments in multiple myeloma. Best Pract Res Clin Haematol 2007;20:797–816.
   PubMed Web of Science ®Google Scholar
• Richardson P, Mitsiades C, Schlossman R, et al. The treatment of relapsed and refractory multiple myeloma. Hematology Am Soc Hematol Educ Program 2007:317–323.
   PubMedGoogle Scholar
• DitzelSantos D, Ho AW, Tournilhac O, et al. Establishment of BCWM.1 cell line for Waldenstrom’s macroglobulinemia with productive in vivo engraftment in SCID-hu mice. Exp Hematol 2007;35:1366–1375.
   PubMed Web of Science ®Google Scholar
• Sun JY, Xu L, Tseng H, et al. Histone deacetylase inhibitors demonstrate significant preclinical activity as single agents, and in combination with bortezomib in Waldenstrom’s macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011;11:152–156.
   PubMed Web of Science ®Google Scholar
• Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006;58:621–681.
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002;20:4420–4427.
   PubMed Web of Science ®Google Scholar
• Pei XY, Dai Y, Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 2004;10:3839–3852.
   PubMed Web of Science ®Google Scholar
• Catley L, Weisberg E, Kiziltepe T, et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006;108:3441–3449.
   PubMed Web of Science ®Google Scholar
• Yuan J, Horvitz HR. A first insight into the molecular mechanisms of apoptosis. Cell 2004;116:S53–S56, 1 p following S59.
   PubMedGoogle Scholar
• Guicciardi ME, Mott JL, Bronk SF, et al. Cellular inhibitor of apoptosis 1 (cIAP-1) degradation by caspase 8 during TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. Exp Cell Res 2011;317:107–116.
   PubMed Web of Science ®Google Scholar
• Doyle BT, O’Neill AJ, Newsholme P, et al. The loss of IAP expression during HL-60 cell differentiation is caspase-independent. J Leukoc Biol 2002;71:247–254.
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades CS, Richardson PG, et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003;101:4055–4062.
   PubMed Web of Science ®Google Scholar
• Yu C, Rahmani M, Conrad D, et al. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood 2003;102:3765–3774.
   PubMed Web of Science ®Google Scholar
• Zhang QL, Wang L, Zhang YW, et al. The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis. Leukemia 2009;23:1507–1514.
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Small GW, Shi YY. Evidence that inhibition of p44/42 mitogen-activated protein kinase signaling is a factor in proteasome inhibitor-mediated apoptosis. J Biol Chem 2002;277:27864–27871.
   PubMed Web of Science ®Google Scholar
• Lin H, Chen C, Li X, et al. Activation of the MEK/MAPK pathway is involved in bryostatin1-induced monocytic differenciation and up-regulation of X-linked inhibitor of apoptosis protein. Exp Cell Res 2002;272:192–198.
   PubMed Web of Science ®Google Scholar
• Vrana JA, Grant S. Synergistic induction of apoptosis in human leukemia cells (U937) exposed to bryostatin 1 and the proteasome inhibitor lactacystin involves dysregulation of the PKC/MAPK cascade. Blood 2001;97:2105–2114.
   PubMed Web of Science ®Google Scholar
• Leleu X, Jia X, Runnels J, et al. The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood 2007;110:4417–4426.
   PubMed Web of Science ®Google Scholar